Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice

References

• Ling YL, Rascati KL, Pawaskar M. Direct and indirect costs among patients with binge-eating disorder in the United States. Int J Eat Disord. 2017;50(5):523–532.
   PubMed Web of Science ®Google Scholar
• Cossrow N, Pawaskar M, Witt EA, et al. Estimating the prevalence of binge eating disorder in a community sample from the United States: comparing DSM-IV-TR and DSM-5 criteria. J Clin Psychiatry. 2016;77(8):e968–e974.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904–914.
   PubMed Web of Science ®Google Scholar
• Hudson JI, Hiripi E, Pope HG Jr, et al. The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiatry. 2007;61(3):348–358.
   PubMed Web of Science ®Google Scholar
• Grilo CM, White MA, Barnes RD, et al. Psychiatric disorder co-morbidity and correlates in an ethnically diverse sample of obese patients with binge eating disorder in primary care settings. Compr Psychiatry. 2013 Apr;54(3):209–216.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
   Google Scholar
• National Institute for Health and Care Excellence. Eating disorders: recognition and treatment; 2017. [cited 2019 Jan 23]. Available from: nice.org.uk/guidance/ng69
   Google Scholar
• American Psychiatric Association. Guideline watch: practice guidelines for the treatment of patients with eating disorder. 3rd ed. Arlington, VA: American Psychiatric Publishing. 2012.
   Google Scholar
• Wilfley DE, Welch RR, Stein RI, et al. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry. 2002;59:713–721.
   PubMed Web of Science ®Google Scholar
• Peterson CB, Mitchell JE, Engbloom S, et al. Group cognitive behavioral treatment of binge eating disorder: a comparison of therapist-led versus self-help formats. Int J Eat Disord. 1998;24:125–136.
   PubMed Web of Science ®Google Scholar
• Agras WS, Telch CF, Arnow B, et al. Does interpersonal therapy help patients with binge eating disorder who fail to respond to cognitive-behavioral therapy? J Consult Clin Psychol. 1995;63:356–360.
   PubMed Web of Science ®Google Scholar
• Riva G, Bacchetta M, Cesa G, et al. Six-month follow-up of in-patient experiential cognitive therapy for binge eating disorders. Cyberpsychol Behav. 2003;6:251–258.
   PubMedGoogle Scholar
• Grilo C, Masheb RM, Wilson GT, et al. Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge eating disorder: a randomized controlled trial. J Consult Clin Psychol. 2011 Oct;79(5):675–685.
   PubMed Web of Science ®Google Scholar
• Calugi S, Ruocco A, El Ghoch M, et al. Residential cognitive-behavioral weight-loss intervention for obesity with and without binge-eating disorder: a prospective case-control study with five-year follow-up. Int J Eat Disord. 2016 Jul;49(7):723–730.
   PubMed Web of Science ®Google Scholar
• Vyvanse® - lisdexamfetamine dimesylate. Full prescribing information. Wayne (PA): Shire US Inc; 2015 [cited Jul 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021977s010s015lbl.pdf
   Google Scholar
• Guerdjikova AI, Mori N, Casuto LS, et al. Novel pharmacologic treatment in acute binge eating disorder—role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833–841.
   PubMed Web of Science ®Google Scholar
• Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2006;256(Suppl S1):i26–i31.
   PubMedGoogle Scholar
• Mattos P, Saboya E, Ayrao V, et al. Comorbid eating disorders in a Brazilian attention-deficit/hyperactivity disorder adult clinical sample. Rev Bras Psiquiatr. 2004;26(4):248–250.
   PubMedGoogle Scholar
• Surman CB, Randall ET, Biederman J. Association between attention-deficit/hyperactivity disorder and bulimia nervosa: analysis of 4 case-control studies. J Clin Psychiatry. 2006;67(3):351–354.
   PubMed Web of Science ®Google Scholar
• Wentz E, Lacey JH, Waller G, et al. Childhood onset neuropsychiatric disorders in adult eating disorder patients. A pilot study. Eur Child Adolesc Psychiatry. 2005;14(8):431–437.
   PubMed Web of Science ®Google Scholar
• Yates WR, Lund BC, Johnson C, et al. Attention-deficit hyperactivity symptoms and disorder in eating disorder inpatients. Int J Eat Disord. 2009;42(4):375–378.
   PubMed Web of Science ®Google Scholar
• Bello NT, Hajnal A. Dopamine and binge eating behaviors. Pharmacol Biochem Behav. 2010;97(1):25–33.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390–398.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge- eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–246.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251–1260.
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Ferreira-Cornwell MC, et al. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017 Sep 1;74(9):903–910.
   PubMed Web of Science ®Google Scholar
• Gasior M, Hudson J, Quintero J, et al. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017 Jun;37(3):315–322.
   PubMed Web of Science ®Google Scholar
• Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry. 1992;49:139–147.
   PubMed Web of Science ®Google Scholar
• Wang GJ, Geliebter A, Volkow ND, et al. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring). 2011;19(8):1601–1608.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Tortorella A, Castaldo E, et al. Association of a functional serotonin transporter gene polymorphism with binge eating disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(1):7–9.
   PubMed Web of Science ®Google Scholar
• Latagliata EC, Patrono E, Puglisi-Allegra S, et al. Food seeking in spite of harmful consequences is under prefrontal cortical noradrenergic control. BMC Neurosci. 2010;11:15.
   PubMed Web of Science ®Google Scholar
• Fletcher PJ, Paterson IA. A comparison of the effects of tryptamine and 5-hydroxytryptamine on feeding following injection into the paraventricular nucleus of the hypothalamus. Pharmacol Biochem Behav. 1989;32:907–911.
   PubMed Web of Science ®Google Scholar
• Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995;374(6522):542–546.
   PubMed Web of Science ®Google Scholar
• Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009;587(Pt 1):49–60.
   PubMed Web of Science ®Google Scholar
• Laederach-Hofmann K, Graf C, Horber F, et al. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord. 1999;26(3):231–244.
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 1998;155(12):1756–1762, 78.
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Spurell E, Hohlstein LA, et al. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health. 2003;6(2):147–151.
   PubMedGoogle Scholar
• Greeno CG, Wing RR. A double blind, placebo-controlled trial of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr. 1996;64:267–273.
   PubMed Web of Science ®Google Scholar
• Arnold LM, McElroy SL, Hudson JI, et al. A placebo-controlled, randomized trial of fluoxetine in the treat- ment of binge-eating disorder. J Clin Psychiatry. 2002;63(11):1028–1033.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57(3):301–309.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157:1004–1046.
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Capasso A. Treatment of binge eating disorder with sertraline: a randomized controlled trial. Biomed Res. 2004;16:89–91.
   Google Scholar
• Leombruni P, Piero` A, Brustolin A, et al. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol. 2006;21:181–188.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AL, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 2008;23:1–11.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Malhotra S, et al. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychyatry. 2003;64:807–813.
   PubMed Web of Science ®Google Scholar
• Malhotra S, King KH, Welge JA, et al. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry. 2002;63:802–806.
   PubMed Web of Science ®Google Scholar
• Leombruni P, Lavagnino L, Gastaldi F, et al. Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial. Hum Psychopharmacol. 2009;24:483–488.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorder: a placebo controlled trial. Int J Eat Disord. 2011. DOI:10.1002/eat20946
   Web of Science ®Google Scholar
• Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049–1056.
   PubMedGoogle Scholar
• Calandra C, Russo RG, Luca M. Bupropion versus Sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study. Psychiatr Q. 2012;83:177–185.
   PubMed Web of Science ®Google Scholar
• White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400–406.
   PubMed Web of Science ®Google Scholar
• Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets. 2004 Apr;5(3):301–307.
   PubMed Web of Science ®Google Scholar
• Chukwu J, Delanty N, Webb D, et al. Weight change, genetics and antiepileptic drugs. Expert Rev Clin Pharmacol. 2014 Jan;7(1):43–51.
   PubMed Web of Science ®Google Scholar
• Topamax® Highlights of Prescribing information. Food and drug administration; 2012 [cited Jul 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf
   Google Scholar
• Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997;54:752–773.
   PubMed Web of Science ®Google Scholar
• Smith U, Axelsen M, Hellebö-Johanson E, et al. Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity. Obes Res. 2000;8(Suppl 1):105.
   Google Scholar
• McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004 Nov;65(11):1463–1469.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Capece JA, et al. Topiramate binge eating disorder research group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007 May 1;61(9):1039–1048.
   PubMed Web of Science ®Google Scholar
• Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68(9):1324–1332.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol. 2009;24:150–158.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge eating disorder: an open label, prospective trial. J Clin Psychiatry. 2004;65:50–56.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Guerdjikowa AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67:1897–1906.
   PubMed Web of Science ®Google Scholar
• Holderness C, Brooks-Gunn J, Warren M. Co-morbidity of eating disorders and substance abuse review of the literature. Int J Eat Disord. 1994;16:1–34.
   PubMed Web of Science ®Google Scholar
• Berner LA, Bocarsly ME, Hoebel BG, et al. Pharmacological interventions for binge eating: lessons from animal models, current treatments, and future directions. Curr Pharm Des. 2011;17(12):1180–1187.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabi-noid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia. Neuropsychopharmacology. 2005;30(6):1216–1221.
   PubMed Web of Science ®Google Scholar
• Bulik CM, Klump KL, Thornton L, et al. Alcohol use disorder comorbidity in eating disorders: a multicenter study. J Clin Psychiatry. 2004;65:1000–1006.
   PubMed Web of Science ®Google Scholar
• Broft AI, Spanos A, Corwin RL, et al. Baclofen for binge eating: an open-label trial. Int J Eat Disord. 2007 Dec;40(8):687–691.
   PubMed Web of Science ®Google Scholar
• Corwin RL, Boan J, Peters KF, et al. Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behav Pharmacol. 2012 Sep;23(5–6):616–625.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Blom TJ, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46(3):239–245.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Winstanley EL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord. 2011 Jan;44(1):81–90.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Walsh B, Shan K, et al. Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther. 2017 Oct;34(10):2307–2315.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595–605.
   PubMed Web of Science ®Google Scholar
• Alger SA, Schwalberg MD, Bigaouette JM, et al. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Lancet. 2010;376(9741):595–605.
   PubMedGoogle Scholar
• Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591–602.
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–917.
   PubMed Web of Science ®Google Scholar
• Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrocloride (BTS 54 524), a new antidepressant which induces rapid naradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584.
   PubMed Web of Science ®Google Scholar
• Stricker-Krograd A, Burlet C, Souqurt AM. Effects of sibutramine on feeding behaviour in dietary-induced obesity: a role of dietary components. Int J Obes. 1995;19(suppl12):145.
   Google Scholar
• Kaiser PE, Hinson JL. Sibutramine: dose response and plasma metabolic concentrations in weight loss. J Clin Pharmacol. 1994;34:1019.
   Google Scholar
• Van Gaal LF, Wauters MA, De Leew IH. Anti-obesity drugs, what does sibutramine offer? An analysis of its potential contribution of obesity treatment. Exp Clin Endocrinol Diabetes. 1998;106:35–40.
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther. 2005 Jan–Feb;22(1):25–31.
   PubMed Web of Science ®Google Scholar
• Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003 Nov;60(11):1109–1116.
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008 Jan;165(1):51–58.
   PubMed Web of Science ®Google Scholar
• Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity. 2007;15:2712–2722.
   PubMed Web of Science ®Google Scholar
• Vetter ML, Faulconbridge LF, Webb VL, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010;6:578–588.
   PubMed Web of Science ®Google Scholar
• Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005 Oct;13(10):1701–1708.
   PubMedGoogle Scholar
• Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and or list at for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005 May 15;57(10):1193–1201.
   PubMed Web of Science ®Google Scholar
• Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab. 2003 5;May(3):180–188.
   Google Scholar
• Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 2013 Mar;51(3):167–175.
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes Metab. 2009;11(Suppl 3):26–34.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. Randomized, controlled trial of 3.0 mg of liraglutide in weight management.; SCALE obesity and prediabetes NN8022-1839 study group. N Engl J Med. 2015 Jul 2;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study. Obes Res Clin Pract. 2015 May–Jun;9(3):301–304.
   PubMed Web of Science ®Google Scholar
• Mc Tavish D, Heel RC. Dexenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drug Eval. 1992;43:713–733.
   Google Scholar
• Stunkard A, Berkowitz R, Tanrikut C, et al. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry. 1996 Nov;153(11):1455–1459.
   PubMed Web of Science ®Google Scholar
• de Zwaan M. “Binge-Eating”: was stoppt die Essanfälle? MMW Fortschr Med. 2010;152(34–35):26.
   PubMedGoogle Scholar